Beryl McCormick1, Kathryn Winter2, Clifford Hudis2, Henry Mark Kuerer2, Eileen Rakovitch2, Barbara L Smith2, Nour Sneige2, Jennifer Moughan2, Amit Shah2, Isabelle Germain2, Alan C Hartford2, Afshin Rashtian2, Eleanor M Walker2, Albert Yuen2, Eric A Strom2, Jeannette L Wilcox2, Laura A Vallow2, William Small2, Anthony T Pu2, Kevin Kerlin2, Julia White2. 1. Beryl McCormick and Clifford Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; Kathryn Winter and Jennifer Moughan, Radiation Therapy Oncology Group Statistical Center, Philadelphia; Amit Shah, York Cancer Center, York; Albert Yuen, Reading Hospital and Medical Center, Reading, PA; Henry Mark Kuerer, Nour Sneige, and Eric A. Strom, The University of Texas MD Anderson Cancer Center, Houston, TX; Barbara L. Smith, Massachusetts General Hospital, Boston, MA; Alan C. Hartford, Dartmouth Hitchcock Medical Center, Lebanon, NH; Afshin Rashtian, University of Southern California, Los Angeles, Los Angeles; Anthony T. Pu, Radiological Associates of Sacramento, Sacramento, CA; Eleanor M. Walker, Henry Ford Hospital, Detroit, MI; Jeannette L. Wilcox, Greenville SC Community Clinical Oncology Program (CCOP), Greenville, SC; Laura A. Vallow, Mayo Clinic, Jacksonville, FL; William Small Jr, Northwestern University Feinberg School of Medicine, Chicago, IL; Kevin Kerlin, Southeast Cancer Control Consortium CCOP, Winston-Salem, NC; Julia White, James Cancer Hospital, Ohio State University, Columbus, OH; Eileen Rakovitch, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario; and Isabelle Germain, L'Hotel-Dieu de Quebec, Quebec, Quebec, Canada. mccormib@mskcc.org. 2. Beryl McCormick and Clifford Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; Kathryn Winter and Jennifer Moughan, Radiation Therapy Oncology Group Statistical Center, Philadelphia; Amit Shah, York Cancer Center, York; Albert Yuen, Reading Hospital and Medical Center, Reading, PA; Henry Mark Kuerer, Nour Sneige, and Eric A. Strom, The University of Texas MD Anderson Cancer Center, Houston, TX; Barbara L. Smith, Massachusetts General Hospital, Boston, MA; Alan C. Hartford, Dartmouth Hitchcock Medical Center, Lebanon, NH; Afshin Rashtian, University of Southern California, Los Angeles, Los Angeles; Anthony T. Pu, Radiological Associates of Sacramento, Sacramento, CA; Eleanor M. Walker, Henry Ford Hospital, Detroit, MI; Jeannette L. Wilcox, Greenville SC Community Clinical Oncology Program (CCOP), Greenville, SC; Laura A. Vallow, Mayo Clinic, Jacksonville, FL; William Small Jr, Northwestern University Feinberg School of Medicine, Chicago, IL; Kevin Kerlin, Southeast Cancer Control Consortium CCOP, Winston-Salem, NC; Julia White, James Cancer Hospital, Ohio State University, Columbus, OH; Eileen Rakovitch, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario; and Isabelle Germain, L'Hotel-Dieu de Quebec, Quebec, Quebec, Canada.
Abstract
PURPOSE: The Radiation Therapy Oncology Group 9804 study identified good-risk patients with ductal carcinoma in situ (DCIS), a breast cancer diagnosis found frequently in mammographically detected cancers, to test the benefit of radiotherapy (RT) after breast-conserving surgery compared with observation. PATIENTS AND METHODS: This prospective randomized trial (1998 to 2006) in women with mammographically detected low- or intermediate-grade DCIS, measuring less than 2.5 cm with margins ≥ 3 mm, compared RT with observation after surgery. The study was designed for 1,790 patients but was closed early because of lower than projected accrual. Six hundred thirty-six patients from the United States and Canada were entered; tamoxifen use (62%) was optional. Ipsilateral local failure (LF) was the primary end point; LF and contralateral failure were estimated using cumulative incidence, and overall and disease-free survival were estimated using the Kaplan-Meier method. RESULTS: Median follow-up time was 7.17 years (range, 0.01 to 11.33 years). Two LFs occurred in the RT arm, and 19 occurred in the observation arm. At 7 years, the LF rate was 0.9% (95% CI, 0.0% to 2.2%) in the RT arm versus 6.7% (95% CI, 3.2% to 9.6%) in the observation arm (hazard ratio, 0.11; 95% CI, 0.03 to 0.47; P < .001). Grade 1 to 2 acute toxicities occurred in 30% and 76% of patients in the observation and RT arms, respectively; grade 3 or 4 toxicities occurred in 4.0% and 4.2% of patients, respectively. Late RT toxicity was grade 1 in 30%, grade 2 in 4.6%, and grade 3 in 0.7% of patients. CONCLUSION: In this good-risk subset of patients with DCIS, with a median follow-up of 7 years, the LF rate was low with observation but was decreased significantly with the addition of RT. Longer follow-up is planned because the timeline for LF in this setting seems protracted.
RCT Entities:
PURPOSE: The Radiation Therapy Oncology Group 9804 study identified good-risk patients with ductal carcinoma in situ (DCIS), a breast cancer diagnosis found frequently in mammographically detected cancers, to test the benefit of radiotherapy (RT) after breast-conserving surgery compared with observation. PATIENTS AND METHODS: This prospective randomized trial (1998 to 2006) in women with mammographically detected low- or intermediate-grade DCIS, measuring less than 2.5 cm with margins ≥ 3 mm, compared RT with observation after surgery. The study was designed for 1,790 patients but was closed early because of lower than projected accrual. Six hundred thirty-six patients from the United States and Canada were entered; tamoxifen use (62%) was optional. Ipsilateral local failure (LF) was the primary end point; LF and contralateral failure were estimated using cumulative incidence, and overall and disease-free survival were estimated using the Kaplan-Meier method. RESULTS: Median follow-up time was 7.17 years (range, 0.01 to 11.33 years). Two LFs occurred in the RT arm, and 19 occurred in the observation arm. At 7 years, the LF rate was 0.9% (95% CI, 0.0% to 2.2%) in the RT arm versus 6.7% (95% CI, 3.2% to 9.6%) in the observation arm (hazard ratio, 0.11; 95% CI, 0.03 to 0.47; P < .001). Grade 1 to 2 acute toxicities occurred in 30% and 76% of patients in the observation and RT arms, respectively; grade 3 or 4 toxicities occurred in 4.0% and 4.2% of patients, respectively. Late RT toxicity was grade 1 in 30%, grade 2 in 4.6%, and grade 3 in 0.7% of patients. CONCLUSION: In this good-risk subset of patients with DCIS, with a median follow-up of 7 years, the LF rate was low with observation but was decreased significantly with the addition of RT. Longer follow-up is planned because the timeline for LF in this setting seems protracted.
Authors: B Fisher; J Dignam; N Wolmark; E Mamounas; J Costantino; W Poller; E R Fisher; D L Wickerham; M Deutsch; R Margolese; N Dimitrov; M Kavanah Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: J P Julien; N Bijker; I S Fentiman; J L Peterse; V Delledonne; P Rouanet; A Avril; R Sylvester; F Mignolet; H Bartelink; J A Van Dongen Journal: Lancet Date: 2000-02-12 Impact factor: 79.321
Authors: Joan Houghton; W D George; Jack Cuzick; Catherine Duggan; Ian S Fentiman; Margaret Spittle Journal: Lancet Date: 2003-07-12 Impact factor: 79.321
Authors: Julia S Wong; Yu-Hui Chen; Michele A Gadd; Rebecca Gelman; Susan C Lester; Stuart J Schnitt; Dennis C Sgroi; Barbara J Silver; Barbara L Smith; Susan L Troyan; Jay R Harris Journal: Breast Cancer Res Treat Date: 2013-12-18 Impact factor: 4.872
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Wendy A Woodward; Nour Sneige; Kathryn Winter; Henry Mark Kuerer; Clifford Hudis; Eileen Rakovitch; Barbara L Smith; Lori J Pierce; Isabelle Germano; Anthony T Pu; Eleanor M Walker; David Lawrence Grisell; Julia R White; Beryl McCormick Journal: J Clin Pathol Date: 2014-09 Impact factor: 3.411
Authors: Jennifer Y Sheng; Cesar A Santa-Maria; Neha Mangini; Haval Norman; Rima Couzi; Raquel Nunes; Mary Wilkinson; Kala Visvanathan; Roisin M Connolly; Evanthia T Roussos Torres; John H Fetting; Deborah K Armstrong; Jessica J Tao; Lisa Jacobs; Jean L Wright; Elissa D Thorner; Christine Hodgdon; Samantha Horn; Antonio C Wolff; Vered Stearns; Karen L Smith Journal: JCO Oncol Pract Date: 2020-06-30
Authors: Icro Meattini; Marta Scorsetti; Fiorenza De Rose; Maria Carmen De Santis; Bruno Meduri; Ciro Franzese; Davide Franceschini; Pierfrancesco Franco; Nadia Pasinetti; Valentina Lancellotta; Patrizia Giacobazzi; Eliana La Rocca; Elisa D'Angelo; Laura Lozza; Lorenzo Livi Journal: J Cancer Res Clin Oncol Date: 2021-01-02 Impact factor: 4.553
Authors: Laura S Dominici; Monica Morrow; Elizabeth Mittendorf; Jennifer Bellon; Tari A King Journal: Curr Probl Surg Date: 2016-11-29 Impact factor: 1.909